Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

9th Annual Innate Killer Summit

9th Annual Innate Killer Summit


Date of beginning

Monday, 18 March 2024


3 days


San Diego


United States


Phoebe Morris


This email address is being protected from spambots. You need JavaScript enabled to view it.


The Innate Killer Summit is returning for the 9th year as the must-attend meeting for the NK community, committed to addressing the critical challenges across all NK-targeted therapeutic types. Join this focused, collaborative forum spanning Preclinical, Clinical Translation and CMC and Process development to brainstorm with industry pioneers on the best approaches to enhance efficacy and persistence as well as reduce the cost of production. Showcasing innovation across biopharma and academia, we have collaborated with MD Anderson, Replay Bio, Pfizer, Glycostem, Senti Bio, XNK Therapeutics, Sanofi, Zelluna Immunotherapy and many more to uncover translational lessons learned in liquid and solid tumor indications. URLs:Tickets: Brochure:  Date and Time: On Mon, 18 Mar 2024 08:00 - Wed, 20 Mar 2024 17:00 Venue Details: San Diego Marriott Del Mar, 11966 El Camino Real, San Diego, California, 92130, United States Prices:Drug Developer Pricing - Conference Only: USD 2999.00,Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,Service Provider Pricing - Conference Only: USD 3699.00,Service Provider Pricing - Conference + Workshop Day: USD 5097.00,Academic Pricing - Conference Only: USD 2599.00,Academic Pricing - Conference + Workshop Day: USD 4096.00,Academic Pricing - Conference + Bootcamp Day: USD 4096.00,Service Provider Pricing - Conference + Bootcamp Day: USD 5097.00,Drug Developer Pricing - Conference + Bootcamp Day: USD 4197.00 Speakers: Allen Feng, Founder and Chief Scientific Officer, HebeCell, Dan Kaufman, Professor/Co-founder, University of California San Diego / Shoreline Biosciences, Emilie Gauthy, Head of CMC, Zelluna Immunotherapy, Fred Aslan, CEO, Artiva Biotherapeutics, Johan Liwing, CEO, XNK Therapeutics, Juliana Vergara, Principal Scientist, Senti Bio, Mark Frohlich, Chief Executive Officer, Indapta Therapeutics, Raphael Ognar, CEO, NKILT Therapeutics, Robert Igarashi, Head of Discovery, Sanof